Drug Profile
Research programme: anti-infectives - Zymenex/Genmab
Alternative Names: ACE-5001; ACE-5003; ACE-5033Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ACE BioSciences
- Developer Zymenex A/S
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Aspergillosis; Mycoses
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Aspergillosis in Denmark (Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Mycoses in Denmark (Injection)
- 09 Nov 2009 ACE BioSciences has been acquired by Zymenex A/S